Spasmodic torticollis

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Saturday, May 23, 2020 - 6:00am

The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.

Key Points: 
  • The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.
  • Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives.
  • Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year.
  • How do patients with cervical dystonia (CD) experience their botulinum neurotoxin type a (BoNT-A) treatment cycle: results from an international online survey.

FDA Approves US WorldMeds' MYOBLOC® (rimabotulinumtoxinB) Injection for Chronic Sialorrhea

Monday, August 26, 2019 - 4:49pm

The most common adverse reactions reported in all studies for chronic sialorrhea were dry mouth, dental caries, and dysphagia.1,2

Key Points: 
  • The most common adverse reactions reported in all studies for chronic sialorrhea were dry mouth, dental caries, and dysphagia.1,2
    "We are committed to helping patients who struggle with confidence due to their sialorrhea.
  • MYOBLOC was first approved by the FDA in 2000 for the treatment of adults with cervical dystonia.
  • - injected into the salivary glands (parotid and submandibular glands) and used to treat chronic sialorrhea in adults.
  • The effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.

Global Cervical Dystonia Therapeutics Market to 2023: Alternatives to Botulinum Toxins and Other Therapeutics will Provide Market Challenges

Wednesday, November 21, 2018 - 1:00pm

The cervical dystonia therapeutics market will register a CAGR of almost 5% by 2023.

Key Points: 
  • The cervical dystonia therapeutics market will register a CAGR of almost 5% by 2023.
  • With the rise in reimbursement programs for botulinum neurotoxin injections, there is a growing demand for treatment of cervical dystonia.
  • Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia.
  • The global cervical dystonia therapeutics industry is forecasted to witness a steady growth owing to the expected approval of late-stage molecules in the pipeline for the treatment of cervical dystonia.